The U.S. Food and Drug Administration is scoffing at a “Doe” lawsuit filed by a company attorney trying to prevent being identified in an agency inspection report on the grounds disclosure would cause irreparable harm to the lawyer’s reputation and career.

The unusual “reverse FOIA” case, is based on flimsy legal arguments that don’t come close to meeting the narrow public-disclosure exceptions contained in the Food, Drug and Cosmetic Act, the agency asserts in a recently filed motion to dismiss.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]